Literature DB >> 8893282

Solubility behavior, phase transition, and structure-based nucleation inhibition of etanidazole in aqueous solutions.

M B Maurin1, S M Rowe, K S Field, R C Swintosky, M A Hussain.   

Abstract

PURPOSE: The solubility behavior, phase transition and inhibition of the nucleation process of etanidazole were characterized.
METHODS: Solubility measurements as a function of time permitted characterization of the solubility behavior and phase transition. The precipitate from saturated solutions was isolated and characterized by differential scanning calorimetry, polarized light microscopy, x-ray powder diffraction and coulometric analysis. The physical stability of metastable systems was examined in the presence of various structure-based nucleation inhibitors.
RESULTS: Etanidazole is soluble in water with an equilibrium solubility of 68.1 mg/mL, pH 6.5 with changes in pH having virtually no effect on the solubility. Etanidazole reaches concentrations in excess of 150 mg/mL within one hour. Etanidazole solutions prepared at 150 mg/ mL contained crystals after rotating for 24 hours. The crystals were isolated and characterized as etanidazole monohydrate. the solubility of etanidazole monohydrate in water increased with time reaching an equilibrium solubility of 68 mg/mL after 24 hours. Therefore, the solubility studies were actually determining the solubility of the more stable monohydrate from of etanidazole. Etanidazole solutions at concentrations of 50, 100 and 150 mg/mL were stabilized to varying degrees with structure-based nucleation inhibitors (imidazole, ethanolamine or diethanolamine).
CONCLUSIONS: Anhydrous etanidazole undergoes a transition in aqueous solutions to the more stable monohydrate when the solubility of the monohydrate is exceeded. The physical stability of etanidazole solutions at 4 degrees C is improved following autoclaving. The addition of structure-based nucleation inhibitors effectively stabilized the metastable systems.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8893282     DOI: 10.1023/a:1016038403921

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  9 in total

1.  DISSOLUTION BEHAVIOR OF CRYSTALLINE SOLVATED AND NONSOLVATED FORMS OF SOME PHARMACEUTICALS.

Authors:  E SHEFTER; T HIGUCHI
Journal:  J Pharm Sci       Date:  1963-08       Impact factor: 3.534

2.  Effect of crystal form, cortisone alcohol and agitation on crystal growth of cortisone acetate in aqueous suspensions.

Authors:  J E Carless; M A Moustafa; H D Rapson
Journal:  J Pharm Pharmacol       Date:  1968-08       Impact factor: 3.765

Review 3.  Pharmaceutical applications of solid dispersion systems.

Authors:  W L Chiou; S Riegelman
Journal:  J Pharm Sci       Date:  1971-09       Impact factor: 3.534

4.  Cholesterol particle growth and dissolution rates II. Retardation effects of cholate.

Authors:  H Y Saad; W I Higuchi
Journal:  J Pharm Sci       Date:  1965-09       Impact factor: 3.534

5.  Enhancement of antitumor activity of alkylating agents by the radiation sensitizer misonidazole.

Authors:  J J Clement; M S Gorman; I Wodinsky; R Catane; R K Johnson
Journal:  Cancer Res       Date:  1980-11       Impact factor: 12.701

6.  Initial report of the phase I trial of the hypoxic cell radiosensitizer SR-2508.

Authors:  C N Coleman; R C Urtasun; T H Wasserman; S Hancock; J W Harris; J Halsey; V K Hirst
Journal:  Int J Radiat Oncol Biol Phys       Date:  1984-09       Impact factor: 7.038

7.  Inhibition of glutathione peroxidase and glutathione transferase in mouse liver by misonidazole.

Authors:  K S Kumar; J F Weiss
Journal:  Biochem Pharmacol       Date:  1986-09-15       Impact factor: 5.858

Review 8.  Hypoxia-mediated nitro-heterocyclic drugs in the radio- and chemotherapy of cancer. An overview.

Authors:  G E Adams; I J Stratford
Journal:  Biochem Pharmacol       Date:  1986-01-01       Impact factor: 5.858

9.  Phase I/pharmacokinetic/biochemical study of the nitroimadazole hypoxic cell sensitiser SR2508 (etanidazole) in combination with cyclophosphamide.

Authors:  P J O'Dwyer; F P LaCreta; J Walczak; T Cox; S Litwin; J P Hoffman; M Zimny; R L Comis
Journal:  Br J Cancer       Date:  1993-10       Impact factor: 7.640

  9 in total
  2 in total

Review 1.  Hypoxia-active nanoparticles used in tumor theranostic.

Authors:  Yaqin Wang; Wenting Shang; Meng Niu; Jie Tian; Ke Xu
Journal:  Int J Nanomedicine       Date:  2019-05-22

2.  New synthesis and antiparasitic activity of model 5-aryl-1-methyl-4-nitroimidazoles.

Authors:  Haythem A Saadeh; Ibrahim M Mosleh; Mustafa M El-Abadelah
Journal:  Molecules       Date:  2009-07-27       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.